The aim of the present study was to assess the dopaminergic therapy requirements of a cohort of PD patients carrying pathogenic mutations in recessive genes (PRKN, PINK1) and its outcome in terms of motor and non-motor competence of patients. This evidence concerns the gene PRKN and Parkinson disease.